
Upadacitinib tablets
Form: Tablets
Strength: 15 mg, 30 mg
Reference Brands: Rinvoq(US & EU)
Category: Arthritis
Upadacitinib tablets are approved in the EU and US for moderate to severe rheumatoid arthritis. In the EU, AbbVie’s Rinvoq is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality manufacturing. In the US, FDA approval is based on extensive clinical trial data, biosimilarity, and pharmacovigilance. Both regions require detailed dossiers for initial approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for upadacitinib tablets, ensuring adherence to European and American standards for safe, effective autoimmune disease management, helping you navigate complex regulatory processes seamlessly.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Pegloticase injecatble
Strength: 8 mg/1.2 mL vial
Form: Injectable (IV solution)
Reference Brands: Krystexxa (US)
View Details Get EnquiryColchicine tablest
Strength: 0.6 mg
Form: Tablet
Reference Brands: Colcrys(US)
View Details Get EnquiryFebuxostat tablets
Strength: 40 mg, 80 mg
Form: Oral Tablets
Reference Brands: Uloric(EU & US)
View Details Get EnquiryAllopurinol tablets
Strength: 100 mg, 300 mg
Form: Oral Tablets
Reference Brands: Aloprim(US & EU)
View Details Get Enquiry